Deck Kelly 4
4 · Inhibrx Biosciences, Inc. · Filed May 30, 2024
Insider Transaction Report
Form 4
Deck Kelly
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2024-05-30+175,000→ 175,000 totalExercise: $15.86Exp: 2034-05-30→ Common Stock (175,000 underlying)
Footnotes (2)
- [F1]This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
- [F2]Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.